Positions

Overview

  • Introduction:

    Dr. Mayur Narkhede is an assistant professor at the University of Alabama, Birmingham. He completed his residency in Internal Medicine at the Cleveland Clinic Foundation from 2013 to 2016 and a Hematology and Medical Oncology fellowship from Georgetown University in Washington, D.C. He was the chief fellow from 2018 to 2019. He is board-certified in Internal Medicine, Hematology, and Medical Oncology. Dr. Narkhede specialized in the treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, and Chronic Lymphocytic Leukemia.

    Clinical Interests:

    Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Chronic Lymphocytic Leukemia.

    Research: Dr. Narkhede is an active clinical and translational researcher focusing on lymphoid malignancies and Chronic Lymphocytic Leukemia. He is a principal investigator for multiple phase 1 and phase 2 clinical trials conducted at UAB. In addition, his research interest also involves studying imaging and biochemical biomarkers of treatment response and toxicities in non-Hodgkin lymphomas.
  • Principal Investigator On

    Investigator On

  • A Multicenter Retrospective Analysis of Treatment Patterns and Outcomes in Patients with Rare T-Cell Lymphoma Subtypes  awarded by Memorial Sloan-Kettering Cancer Center
  • A Multicenter Retrospective Analysis of Treatment Patterns and Outcomes in Patients with Rare T-Cell Lymphoma Subtypes  awarded by NHS GREATER GLASGOW AND CLYDE
  • Determinants of Efficacy and Toxicities among Patients with Lymphoid and Histiocytic Disorders  awarded by Memorial Sloan-Kettering Cancer Center
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by TG THERAPEUTICS
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by INNATE PHARMA
  • Private Grant  awarded by AFFIMED GMBH
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by ARTIVA BIOTHERAPEUTICS INC
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by TG THERAPEUTICS
  • Private Grant  awarded by INNATE PHARMA
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by VIRACTA INC
  • Private Grant  awarded by TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by ONO PHARMACEUTICAL COMPANY LTD
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • UAB 1923: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) study  awarded by City of Hope
  • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), Maharashtra University of Health Sciences 2012
  • Full Name

  • Mayur Narkhede